The Archive · 4 posts
Innovating the future of biotechnology! 🚀 RTW Biotech Opportunities Ltd (RTW) empowers groundbreaking health solutions. Join the biotech revolution! 🌱
RTW Biotech Opportunities' 2025: NAV up 35.7%, discount narrows to 12%, and FTSE 250 inclusion boosts visibility. A strong rebound year.
March 30, 2026
Showing 3 of 4 posts
RTW Biotech Opportunities' H1 2025 saw a 6% NAV drop but brighter outlook with FTSE All Share inclusion, M&A uptick, and obesity-focused catalysts ahead.
JoshuaSeptember 11, 2025
RTW Biotech backs Aquestive's $75M Anaphylm sublingual film funding, subject to FDA approval as epinephrine alternative.
JoshuaAugust 19, 2025
Merck's $10bn Verona Pharma buyout secures COPD drug Ohtuvayre. Major validation for RTW Biotech after second Merck acquisition. Biotech M&A heats up.
JoshuaJuly 10, 2025
July 10, 2025